A case report of a patient with advanced acinar cell carcinoma of the pancreas: long-term survival with regional, systemic and targeted therapy.

Abstract

Acinar cell carcinoma of the pancreas is an uncommon malignancy for which there are no prospective, randomized data to guide therapy. We describe the clinical course and management of a patient with advanced pancreatic acinar cell carcinoma who is alive seven years after diagnosis using systemic and regional chemotherapies as well as molecularly targeted agents.

• Authors: Celina Ang, Luis A Herran, Diane Reidy Lagunes, David S Klimstra, Nancy E Kemeny
• Journal: Tumori (Tumori) 2013 Mar-Apr Vol. 99 Issue 2 Pg. e61-4 ISSN: 2038-2529 [Electronic] United States
• PMID: 23748831 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antibodies, Monoclonal, Humanized
• Biomarkers, Tumor
• Organoplatinum Compounds
• Radiopharmaceuticals
• Fluorodeoxyglucose F18
• Bevacizumab
• Cetuximab
• Leucovorin
• Fluorouracil
• Camptothecin

Topics

• Aged
• Antibodies, Monoclonal, Humanized (administration & dosage)
• Antineoplastic Combined Chemotherapy Protocols (administration & dosage, therapeutic use)
• Bevacizumab
• Biomarkers, Tumor (analysis)
• Camptothecin (administration & dosage, analogs & derivatives)
• Carcinoma, Acinar Cell (chemistry, diagnosis, drug therapy, secondary)
• Cetuximab
• Fluorodeoxyglucose F18
• Fluorouracil (administration & dosage)
• Humans
• Immunohistochemistry
• Leucovorin (administration & dosage)
• Liver Neoplasms (chemistry, drug therapy, secondary)
• Male
• Molecular Targeted Therapy
• Multimodal Imaging (methods)
• Organoplatinum Compounds (administration & dosage)
• Pancreatic Neoplasms (chemistry, diagnosis, drug therapy, pathology)
• Positron-Emission Tomography
• Radiopharmaceuticals
• Tomography, X-Ray Computed
• Treatment Outcome